{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-188223","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2023-07-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.080597+00:00","generated_at":"2026-06-13T07:47:30.654480+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Inhibikase regains Nasdaq minimum bid price compliance","bullets":["Received Nasdaq notice on July 17, 2023 confirming compliance with Listing Rule 5550(a)(2).","Closing bid price was at or above $1.00 for 10 consecutive business days ended July 14, 2023.","The matter is closed; no further action required from the company."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-188223","json":"https://secwatch.observer/filing/0001193125-23-188223.json","markdown":"https://secwatch.observer/filing/0001193125-23-188223.md","text":"https://secwatch.observer/filing/0001193125-23-188223.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312523188223/0001193125-23-188223-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312523188223/d510291d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T07:47:30.654480+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}